BIOMAT Database Logo BIOMAT Database Logo

[Action of instantaneous-delayed action phenformin, alone or in combined therapy, in 50 hospitalized diabetics]. 1966

J Vague, and P Vague, and P Jaquet, and G Gerolami

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010629 Phenformin A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290) Fenformin,Phenylethylbiguanide
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

J Vague, and P Vague, and P Jaquet, and G Gerolami
[The role of delayed-action instantaneous phenformin in the treatment of diabetes in adults].
May 1966, Journal de medecine de Lyon,
J Vague, and P Vague, and P Jaquet, and G Gerolami
Hyperlactatemia in diabetics with retinopathy during combined sulphonylurea and phenformin therapy.
March 1978, Diabete & metabolisme,
J Vague, and P Vague, and P Jaquet, and G Gerolami
The hypoglycaemic action of phenformin. Studies in diabetics after short-term therapy.
September 1961, Lancet (London, England),
J Vague, and P Vague, and P Jaquet, and G Gerolami
[Results of the phenformin-insulin combination in 50 young diabetics].
September 1968, Le Diabete,
J Vague, and P Vague, and P Jaquet, and G Gerolami
Metabolic abnormalities during combined sulphonylurea and phenformin therapy in maturity-onset diabetics.
June 1978, Diabetologia,
J Vague, and P Vague, and P Jaquet, and G Gerolami
[Action of phenformin (phenylethylbiguanide or DBI) on organo-aciduria in diabetics (Preliminary note)].
November 1960, Jornal da Sociedade das Ciencias Medicas de Lisboa,
J Vague, and P Vague, and P Jaquet, and G Gerolami
[Lactic acidosis in diabetics during phenformin therapy].
December 1975, Ugeskrift for laeger,
J Vague, and P Vague, and P Jaquet, and G Gerolami
[Oral antidiabetic therapy with delayed-action glibenclamide and phenformin in fixed combination].
September 1974, Minerva medica,
J Vague, and P Vague, and P Jaquet, and G Gerolami
Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways.
July 2018, Cancer communications (London, England),
J Vague, and P Vague, and P Jaquet, and G Gerolami
Hyperlactataemia in phenformin-treated diabetics.
January 1972, British medical journal,
Copied contents to your clipboard!